WebOur goal is to address serious medical conditions across multiple and diverse therapeutic areas. Our pipeline is powered by end-to-end research and development capabilities, and … WebAlpha - 1 Liver Disease. ALN-AAT02 is a subcutaneously administered, investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease). ALN-AAT02 utilizes our Enhanced Stabilization Chemistry-Plus (ESC+)-GalNAc delivery platform.
Regeneron Pharmaceutical
WebApr 7, 2024 · The Director of Biostatistics provides leadership and guidance as the statistical expert on a project team or within a therapeutic area, e.g., Infectious Diseases and other broader areas in General ... Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without ... WebSenior Manager, Therapeutic Area Trainer - Oncology Regeneron Basking Ridge, NJ Just now Be among the first 25 applicants エクセル マクロ 情報収集
Senior Manager, Therapeutic Area Trainer - Oncology - LinkedIn
WebSep 27, 2024 · View Brian James' email address (b*****@regene***.com) and phone number. Brian works at Regeneron Pharmaceuticals, Inc. as Senior Director, QA Drug Product and Supply Chain. Brian is based out of Albany, New York Metropolitan Area and works in the Biotechnology Research industry. WebPhysician Scientist, Translational Genetics, Target Discovery and Health Data mining. Tarrytown, New York, United States of America Research and Development R10545. As a … WebTHE REGENERON WAY. Through a year of immense growth, our Regeneron team worked together to maintain our culture of scientific curiosity. By the end of 2024, we had 10,368 … palo alto ignite